drugset / Trial / NCT06906874
Activated Charcoal Use in Chronic Kidney Disease Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
Timeline
- Start
- 2025-08
- Primary completion
- 2025-11
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Activated Charcoal | Other / unclassified | — | Oral |
| Background | Sevelamer | Other / unclassified | — | — |